India, May 13 -- Ahead of US President Donald Trump's visit to Beijing, China's largest drug company, Jiangsu Hengrui Pharmaceutical, has signed a $15.2 billion collaboration and licensing agreement with American pharmaceutical giant Bristol Myers Squibb (BMS). Trump is visiting China from May 13 to 15 for talks with his Chinese counterpart, Xi Jinping, to reach, among others, a trade deal over tariffs and investments.

Jiangsu Hengrui Pharmaceutical, China's largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to $15.2 billion, Hong Kong-based South China Morning Post reported on Tuesday.

The deal adds credibility to Chin...